DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Apple Restores Telegram to App Store After Content Policy Violation 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
NESS ZIONA, Israel, March 26, 2018 -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial statements for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on March 26, 2018, which is available on its website (http://www.sol-gel.com). Shareholders may receive a hard copy of the annual report free of charge upon request.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Patricia L. Bank
Westwicke Partners
+1-415-513-1284
[email protected]
